Study finds precision medicine speeds drug approval

A new study in a special precision medicine-focused issue of Health Affairs showed that drugs targeted at patients in pivotal trials based on genetic characteristics were approved by FDA an average of 1.7 years faster than non-precision medicines.

The paper, which assessed 151 drugs approved by FDA between January 2013 and June 2017, found that precision medicines required 5.8 years for development and FDA review, compared with 7.5 years for non-precision medicines...